HDL drug optimism remains.

Australian Doctor,  April, 2007  

• E-mail
• Print
• Link

By Rebecca Jenkins

THERE is still hope that therapies designed to raise HDL-C to reduce the risk of cardiovascular disease will prove effective - despite recent setbacks, an Australian expert says.

Professor Philip Barter, director of Sydney's Heart Research Institute, said the hypothesis that raising HDL-C was beneficial remained alive.

'HDL is as much a target as it ever was - the question is does it matter how the HDL is raised,' he said.

Professor Barter's comments came as two studies showed neither the experimental drug torecetrapib nor infusions of artificial HDL ...

Read the rest of this article with a Free Trial at HighBeam Research.